Results about: prostate cancer

A high resolution description of the structure and dynamics of proteins is a very useful tool to study the properties and the function of these important biomacromolecules and, most importantly, to understand how changes in sequence or environment can lead to disease.

Researchers at IRB Barcelona identify a possible therapeutic target for Kennedy´s disease and prostate cancer

Activation of the chaperone protein Hsp70 leads to a decrease in the formation of androgen receptor aggregates, which give rise to muscular atrophy in patients with Kennedy´s disease, a rare condition for which no treatment is available.

The results may also be useful in the search for a treatment for castration-resistant prostate cancer, a disease that causes 30,000 death a year in Europe and for which there is no treatment.

The study, which has been published in Nature Communications, is a collaboration with the University of California San Francisco and the University of Michigan. 

The Spanish Association Against Cancer awards funding to five projects at IRB Barcelona

The projects address breast, lung, colon, prostate and melanoma cancer.

Closing in on advanced prostate cancer

Xavier Salvatella, ICREA researcher at IRB Barcelona, ​​proposes a new approach to combat prostate tumour cells that have become unresponsive to the treatments currently available.

The incidence of prostate cancer is increasing worldwide. In the US and Europe, it is one of the most common tumours and among the main causes of death by cancer.

IRB Barcelona’s “Meet Our Scientists” video series brings biomedicine closer to society

The second video, "Magical Choreography" (02:52), is devoted to Xavier Salvatella, ICREA researcher and holder of an ERC grant, awarded in 2015.

This biophysicist studies protein folding using the Androgen receptor as a model—a receptor linked to Kennedy disease —a rare neurodegenerative condition —and also to prostate cancer.

His research could lead to new drug treatments for both conditions. "Doing what we do is an honour but also a responsibility," says the scientist.

2M€ for studying protein motions and their implications for the treatment of prostate cancer

The European Research Council provides funding until 2020 through a Consolidator Grant given to Xavier Salvatella, biophysicist at IRB Barcelona.

It is known that signalling occurs within proteins; however, how these signals are transmitted remains unclear, and it is a question that could transform the field of drug discovery.

The project will focus on the target protein for the treatment of prostate cancer.